Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | FPR1 | P21462 | 2/20 | 0.43 |
| ▸ | FPR2 | P25090 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | CCR4 | P51679 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772884 | 1.00 | PDE10A (0.45) | PDE10AFPR1FPR2USP30AAK1 | |
| SCHEMBL29772858 | 1.00 | PDE10A (0.45) | PDE10AFPR1FPR2USP30AAK1 | |
| SCHEMBL28508706 | 0.88 | PDE10A (0.43) | PDE10AUSP30AAK1DDR1HSD11B1 | |
| SCHEMBL28506133 | 0.88 | PDE10A (0.43) | PDE10AUSP30AAK1DDR1HSD11B1 | |
| SCHEMBL4288048 | 0.87 | PDE10A (0.43) | PDE10AFPR1FPR2USP30AAK1 | |
| SCHEMBL31485219 | 0.87 | PDE10A (0.43) | PDE10AFPR1FPR2USP30AAK1 | |
| SCHEMBL4294688 | 0.87 | PDE10A (0.43) | PDE10AFPR1FPR2USP30AAK1 | |
| SCHEMBL4294928 | 0.84 | ALDH1A1 (0.50) | PDE10AMAPT | |
| SCHEMBL6207573 | 0.83 | FPR1 (0.41) | PDE10AFPR1FPR2USP30AAK1 | |
| SCHEMBL12530374 | 0.83 | HSD17B1 (0.47) | PDE10AFPR1FPR2USP30AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299348-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| WO-2022150461-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150461-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299348-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | TRPM5, TRPM6, TRPM2 | PDE10A 980/4885FPR1 3830/4885FPR2 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.